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Genetic Disorders of the Skeleton: A Developmental Approach
Uwe Kornak and Stefan Mundlos
Institute for Medical Genetics, Charite´ University Hospital, Campus Virchow, Berlin
Although disorders of the skeleton are individually rare, they are of clinical relevance because of their overall
frequency. Many attempts have been made in the past to identify disease groups in order to facilitate diagnosis
and to draw conclusions about possible underlying pathomechanisms. Traditionally, skeletal disorders have been
subdivided into dysostoses, deﬁned as malformations of individual bones or groups of bones, and osteochondro-
dysplasias, deﬁned as developmental disorders of chondro-osseous tissue. In light of the recent advances in molecular
genetics, however, many phenotypically similar skeletal diseases comprising the classical categories turned out not
to be based on defects in common genes or physiological pathways. In this article, we present a classiﬁcation based
on a combination of molecular pathology and embryology, taking into account the importance of development for
the understanding of bone diseases.
Introduction
Genetic disorders affecting the skeleton comprise a large
group of clinically distinct and genetically heterogeneous
conditions. Clinical manifestations range from neonatal
lethality to only mild growth retardation. Although they
are individually rare, disorders of the skeleton are of
clinical relevance because of their overall frequency.
Their clinical diversity makes these disorders often dif-
ﬁcult to diagnose, and many attempts have been made
to delineate single entities or groups of diseases to fa-
cilitate diagnosis. Traditionally, skeletal disorders have
been subdivided into dysostoses, deﬁned as malforma-
tions of individual bones or groups of bones, and os-
teochondrodysplasias, deﬁned as developmental disor-
ders of chondro-osseous tissue. On the basis of clinical
and radiological features, an international group of ex-
perts created a taxonomy called the “Nomenclature and
Classiﬁcation of the Osteochondrodysplasias.” In the
most recent revision, the dysostoses have been incor-
porated into the nomenclature, which also has been
called a “nosology” (Hall 2002). Although this nosology
is based on clinical entities, it also takes into account
the more recent advances in our understanding of the
molecular pathology of skeletal conditions. In many in-
stances, the molecular data support the original clinical
delineation. In other cases, however, it results in the
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grouping of conditions that have a common molecular
origin but that have little in common clinically. For ex-
ample, mutations in COL2A1 can result in such diverse
conditions as lethal achondrogenesis type II and Stickler
dysplasia, which is characterized by moderate growth
retardation, arthropathy, and eye disease. It is now be-
coming increasingly clear that several distinct classiﬁ-
cations are needed that reﬂect, on one hand, the molec-
ular pathology and, on the other, the clinical signs and
symptoms. Several reviews of the rapidly changing mo-
lecular basis of osteochondrodysplasias have been pub-
lished, focusing either on a molecular-pathogenetic clas-
siﬁcation (Mundlos and Olsen 1997; Superti-Furga et
al. 2001) or on more speciﬁc aspects, such as transcrip-
tional dysregulation (Hermanns and Lee 2001).
In this article, we present a classiﬁcation, based on a
combination of molecular pathology and embryology,
that takes into account the importance of development
for the understanding of bone diseases. This concept di-
rectly links the clinical phenotype to key cellular pro-
cesses of skeletal biology, such as proliferation, differ-
entiation, and apoptosis. Skeletal development startswith
the formation of a pattern, a process during which the
number, size, and shape of the individual skeletal ele-
ments are delineated. After the pattern is set, mesenchy-
mal precursor cells migrate to the site of skeletogenesis,
condense, and differentiate. Growth of the skeleton takes
place primarily in the cartilaginous growth plates, highly
specialized organs located at the ends of the long bones.
Bone cells remain active after the growth phase has
ended, to keep the skeleton in homeostasis by a process
called “remodeling.” Accordingly, we have subdivided
skeletal disorders into four major groups: disorders af-
fecting skeletal patterning, condensation/differentiation
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of skeletal precursor structures (“anlagen”), growth, and
homeostasis.
Disorders of Skeletal Patterning
The skeleton arises from three distinct sites. The axial
skeleton, consisting of the vertebrae and ribs, originates
from the somites; the appendicular skeleton has its origin
in mesenchymal cells located in the lateral plate meso-
derm. Most of the craniofacial bones are of neural-crest
origin. Disorders affecting the craniofacial skeleton have
been discussed in detail elsewhere (Wilkie and Morriss-
Kay 2001) and will therefore not be presented here.
The Axial Skeleton
The axial skeleton, consisting of the vertebrae and the
dorsal part of the ribs, is entirely derived from the so-
mites, transient organizational structures of the devel-
oping embryo located on both sides of the neural tube.
Somites are blocks of epithelial cells with a periodic
structure that originate from the paraxial mesoderm.
The formation of new somites and their detachment
from the paraxial mesoderm have to occur in a highly
ordered fashion simultaneously on both sides of the neu-
ral tube, in a craniocaudal direction (ﬁg. 1A). Timed
regulation of the formation and budding of new somites
is given by oscillations of cycling genes that lead towaves
of notch signaling sweeping up the paraxial mesoderm
from the posterior to the anterior pole (Saga and Takeda
2001). In addition to this molecular clock, a stable gra-
dient of Fgf8 expression from the posterior to the an-
terior pole of the embryo allows a spatial coordination
of somite border formation. Dll proteins are notch li-
gands that reside at the cell surface. Their differential
expression determines the size as well as the polarity of
the somites. Any disturbance in this polarity results in
abnormally spaced somites and in fusion of adjacent
somites, as exempliﬁed in the mouse mutant pudgy,
which carries a mutation in Dll3 (Kusumi et al. 1998).
As the somite moves rostrally, it matures and differ-
entiates into the dermatomyotome—a structure giving
rise to the entire appendicular and axial musculature, as
well as to the dorsal epithelium—and the sclerotome,
the primary origin of the axial skeleton (ﬁg. 1B). The
signaling molecule sonic hedgehog (Shh) is the major
signal from the notochord/ﬂoor plate that initiates and
controls sclerotome formation. It is evident that any dis-
turbance of this process will result in abnormal anlagen
of the vertebrae and thus in vertebral malformations.
Conditions with Vertebral Malformations
Abnormalities of the ribs and/or vertebrae are a rel-
atively common ﬁnding in human malformation syn-
dromes. Those that primarily affect the axial skeleton
are summarized under the term “spondylocostal dysos-
toses” (SCDs). Although the causes of the majority of
these genetically heterogeneous conditions remain un-
discovered, one type of dominant SCD has been shown
to be caused bymutations inDLL3 (Bulman et al. 2000).
Similar to the pudgy mutant in the mouse, which is
caused by mutations in the mouse ortholog, Dll3 (Ku-
sumi et al. 1998), affected individuals show a wide va-
riety of vertebral malformations, including fusions and
half vertebrae.
Vertebral malformations are frequently observed inRo-
binow syndrome, a condition that will be discussed fur-
ther below. Robinow syndrome is caused by mutations
in ROR2, an orphan receptor tyrosine kinase (Afzal et
al. 2000; van Bokhoven et al. 2000). The role of ROR2
in somite development remains to be determined.
The Appendicular Skeleton
The limb skeleton originates from the lateral plate
mesoderm, which forms the limb bud as the result of a
series of interactions with the overlying ectoderm. The
mesenchymal cells of the growing limb bud begin to
differentiate to form the various tissues of the limb in a
proximodistal sequence, with structures being laid down
progressively from a region of undifferentiated cells at
the tip of the limb bud, known as the “progress zone.”
The positional identity and thus differentiation of each
cell is controlled by a three-dimensional coordinate sys-
tem consisting of the dorsoventral, proximodistal, and
anteroposterior axes. Each axis is controlled by a par-
ticular set of signaling molecules/pathways produced by
a deﬁned population of cells. Three signaling regions
have been identiﬁed: the apical ectodermal ridge (AER),
mediating limb bud outgrowth (proximodistal axis); ec-
toderm covering the sides of the bud, governing the dor-
soventral pattern; and the zone of polarizing activity
(ZPA), controlling the anteroposterior pattern (ﬁg. 1C).
Many of the signaling molecules that are produced by
these signaling centers have been identiﬁed and char-
acterized. Receptors have been identiﬁed, and intracel-
lular signaling transduction pathways are being unrav-
eled (Capdevila and Izpisua Belmonte 2001).
The AER is an anatomical structure consisting of
densely packed ectodermal cells located at the very tip
of the limb bud. Several different ﬁbroblast growth fac-
tors (FGFs) are expressed and secreted by the AER and
have been shown to be essential and sufﬁcient to initiate
and control outgrowth of the limb. FGF signaling is
conveyed through the FGF receptors, which are ex-
pressed in the underlying mesenchyme. As discussed be-
low, the FGF-signaling system is also important in later
stages of development, when FGFs control skeletal mor-
phogenesis and growth.
The ZPA is a region of mesenchyme located at the
Figure 1 Patterning of the axial and appendicular skeleton. A, Somitogenesis. Presomitic mesoderm on both sides of the neural tube
becomes subdivided into somites in craniocaudal direction. To illustrate the spatial and temporal coordination of somite formation, a time
difference of 90 min between the left and right portion of the presomitic mesoderm is depicted here. Waves of notch expression originating
from the caudal pole of the embryo time the somite border formation so that a new somite is formed every 90 min. Spacial coordination is
conveyed by a gradient of FGF8 expression. Gray shading of newly formed somites represents polarized expression of Dll3. Somites give rise
to several structures, among them the axial skeleton. B, Dorsoventral patterning of the axial skeleton. Each somite subdivides into a derma-
tomyotome, from which the muscles of the extremities are derived, and a sclerotome, which develops into the axial skeleton. This process is
regulated by Shh, which is expressed by the notochord.C, Patterning of the limb buds. The AER is an important signaling center for proximodistal
outgrowth of limb structures. p63 expression is crucial for sustaining the AER. The ZPA directs anteroposterior patterning by expression of
Shh. Under the inﬂuence of Shh, the repressor form of Gli3, Gli3R, is converted to the activating form Gli3A, and a gradient of Shh and Gli3
expression is established. Expression of the Hoxd-cluster genes occurs in a highly ordered fashion as a result of the Shh/Gli3 gradient created
by the ZPA. Wnt7a shows a polarized expression, which is strongest in the dorsal ectoderm of the limb bud. It induces Lmx1 in the underlying
mesenchyme, which has a key role in dorsoventral patterning. D, The result of the patterning process becomes visible as mesenchymal con-
densations at later developmental stages. These condensations either develop into cartilaginous bone precursors in endochondral ossiﬁcation or
are directly transformed into bone in desmal ossiﬁcation.
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posterior limb bud margin. Shh is expressed in this region
and has been shown to be the main mediator of anter-
oposterior patterning (Chiang et al. 1996). Implantation
of Shh-expressing cells can rescue surgical ZPA removal,
and Shh expression from the anterior margin of the limb
bud results in the formation of an anterior ZPA with
subsequent mirror duplication of the entire autopod. Shh
is a secreted molecule that is autoprocessed and subse-
quently modiﬁed by the addition of a cholesterinmolecule
to the last amino acid. Furthermore, a cysteine at the N-
terminus is palmitoylated, thus attaching the protein to
the plasma membrane. Both modiﬁcations are indispens-
able for biological activity. On the other hand, Shh can
form freely diffusible multimers, which allows long-range
effects (Ingham and McMahon 2001). Shh binds to its
receptor, patched (ptc), which in turn inhibits the signaling
of smoothened (smo), a seven-pass membrane protein.
Much of the intracellular hedgehog signaling is commu-
nicated by the family of Gli transcription factors, notably
Gli3. Under the inﬂuence of Shh, the zinc ﬁnger tran-
scription factor Gli3 is converted into the activating form
Gli3A, whereas, otherwise, the repressor form Gli3R pre-
dominates and, in a negative feedback, downregulates
Shh. By this mechanism, Gli3 expression is much stronger
in the anterior than in the posterior limb bud, where Shh
levels are high, thus creating an anteroposterior gradient
that has been shown to be important for limb patterning.
The investigation of the Gli3-deﬁcient mouse mutant ex-
tra toes (Xt) gave some closer insight into the role of Shh
and Gli3 in limb patterning. Surprisingly, the lack of Shh
can be partly rescued by inactivating Gli3. Whereas Shh
deﬁciency leaves only one rudimentary digit, Shh/Gli3
double knockouts show a severe polysyndactyly similar
to Gli3/ mice. The expression of patterning genes like
Hoxd12 and Fgf4 is aberrant in the double mutants. This
places Gli3 downstream of Shh, and it can be concluded
that the Shh/Gli3 pathway imposes a pentadactyl con-
straint on the polydactyl potential of the autopod and
speciﬁes digit identity (Litingtung et al. 2002; te Welscher
et al. 2002).
A member of theWnt family of growth factors,Wnt7a,
has been shown to be important in dorsoventral pattern-
ing. An orthologous pathway is active inDrosophila (Rin-
con-Limas et al. 1999). Expression ofWnt7a in the dorsal
ectoderm of the limb bud upregulates Lmx1b, which be-
longs to the family of LIM homeodomain transcription
factors and forms a dorsoventral gradient (Riddle et al.
1995). This close functional relationship explains why
Wnt7a- andLmx1b-deﬁcientmice both develop autopods
with a double ventral phenotype.
HOX genes from the 5′ region of the A and D clusters
show characteristic stage-dependent expression patterns
that determine the shape and identity of individual skel-
etal elements. HOX genes encode homeodomain-con-
taining transcription factors and are arranged in four
gene clusters (HOXA, HOXB, HOXC, and HOXD)
that comprise a total of 39 genes in humans. Lower-
numberHOX genes are expressed earlier in development
and more anteriorly and proximally than are the higher-
number genes. This pattern of expression is probably
achieved by an as-yet-unknown repression mechanism
that is gradually released during development. At least
for the Hoxd cluster, evidence exists that repression de-
pends on a chromosomal region upstream of Hoxd13
(Kmita et al. 2002). In general, HOX genes seem to lie
downstream of the basic patterning signals—for ex-
ample, those provided by the above-mentioned FGF or
Shh pathways.
Polydactyly Disorders Involving the Hedgehog
Pathway
Polydactyly is a relatively commonmalformation clin-
ically subdivided into the preaxial (additional ﬁnger at
the side of the thumb) and postaxial (additional ﬁnger
at the side of the little ﬁnger) types. Recent evidence from
mouse models has shown that many types of polydactyly
directly or indirectly involve the hedgehog pathway.Mu-
tations in SHH itself, however, cause holoprosencephaly,
a condition characterized by midline defects of the brain
and the face with normal limbs. Mutations in the down-
stream effector of Shh, GLI3, give rise to different phe-
notypes, the mildest of which are postaxial polydactyly
type I (MIM 174200) and preaxial polydactyly type IV
(MIM 174700) (Radhakrishna et al. 1997, 1999). Greig
cephalopolysyndactyly (MIM 175700) is a dominant
disorder that comprises hypertelorism and frontal boss-
ing, as well as syndactyly and pre- or postaxial poly-
syndactyly of variable degrees (Vortkamp et al. 1991).
The most-severe malformations are found in dominant
Pallister-Hall syndrome (MIM 146510), a condition
characterized by (i) malformations of the CNS and, oc-
casionally, holoprosencephaly with midline clefting; (ii)
craniofacial abnormalities; (iii) syndactyly and polydac-
tyly (central and postaxial); and (iv) anal defects (Kang
et al. 1997). No clear genotype/phenotype correlation
exists.
Another protein that possibly acts downstream of Shh
is the human homolog of the Drosophila spalt gene,
SALL1. This zinc ﬁnger transcription factor has been
found to be mutated in Townes-Brocks syndrome (TBS
[MIM 107480]) (Kohlhase et al. 1998). Limb malfor-
mations include biﬁd or triphalangeal thumbs and pre-
axial polydactyly. Further characteristics are abnormal
ears and urogenital, heart, and visceral abnormalities.
In keeping with a role in anteroposterior patterning,
Sall1 is expressed in the AER and the underlying mes-
enchyme. Regardless of the tremendous evolutionary
distance from humans, the orthologous pathway inDro-
sophila also coordinates anteroposterior patterning. The
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Figure 2 SHFM caused by mutations in p63. Whereas the mid-
dle toes of the left foot show the typical features of the disorder, the
right foot appears to be only mildly affected, illustrating the very
variable and often asymmetric manifestation. The phenotype is
thought to arise from an insufﬁciency of the AER during patterning
of the distal limb structures.
exact targets of spalt and Sall1 are still elusive, but it
was demonstrated that the Sall1 protein colocalizes with
the telomere-binding protein PIN2 to pericentromeric
heterochromatin (Netzer et al. 2001). Most mutations
cluster in exon 2 of SALL1 and delete a zinc ﬁnger
domain by truncating the protein, which is thought to
render it nonfunctional.
Preaxial polydactyly is frequently associated with a
triphalangeal thumb (a long ﬁngerlike thumb with three
phalanges instead of two). This condition, triphalan-
geal thumb–polysyndactyly syndrome (TPTPS [MIM
190605]), is inherited as an autosomal dominant trait
with variable expressivity. It has been mapped to chro-
mosome 7, close to the SHH gene (Heutink et al. 1994).
Whereas no TPTPS mutations have been identiﬁed so far,
an intronic deletion and insertion within the neighboring
LMBR1 (Corf2) gene has recently been found in the hu-
man limb amputation condition acheiropodia and in the
polydactylous mouse mutant sasquatch (Ssq), respectively
(Ianakiev et al. 2001; Lettice et al. 2002). These ﬁndings
and the subsequent identiﬁcation of a translocationbreak-
point, in a patient with postaxial polydactyly, in the same
intron as the Ssq insertion (Lettice et al. 2002; Horikoshi
et al. 2003) suggest the existence of a long-range cis en-
hancing element directing Shh expression in the limb. In
the future, the identiﬁcation of the underlying molecular
defect of the mouse limb mutants Hemimelic extra toes
(Hx) and Hammertoe (Hm), which have also been
mapped to this syntenic region and display postaxial poly-
dactyly plus tibial aplasia and syndactyly, may help to
reﬁne the genomic size of an Shh long-range limb en-
hancer element.
Ectrodactyly and Other Absence/Hypoplasia Defects
“Ectrodactyly” is a rather nonspeciﬁc descriptive
term applied to a number of genetic and nongenetic
malformations with absence deformities of the hands/
feet. The great majority of these defects occur unilat-
erally and are nongenetic. The split hand/foot malfor-
mation (SHFM) is genetically heterogeneous and pref-
erentially affects the central part of the distal limb (ﬁg.
2). Similar phenotypes can be produced in the chick,
by surgical removal of the AER. This results in trun-
cation of the limbs at a position corresponding to the
time point of AER ablation, indicating that SHFM may
be caused by similar mechanisms.
The dominant ectrodactyly, ectodermal dysplasia, and
clefting syndrome (EEC [MIM 604292]) was the ﬁrst
condition in which mutations in the p53 homolog p63
were identiﬁed (Celli et al. 1999). In addition to syn-
dactyly and ectrodactyly of the hands and feet, cleft pal-
ate, hypodontia, and diverse signs of ectodermal dys-
plasia can be noted. EEC overlaps with limb-mammary
syndrome (MIM 603543), in which the nipples are hy-
poplastic or absent, and nonsyndromic SHFM (MIM
605289), and all three disorders were shown to be allelic
(Brunner et al. 2002). Expression of the p63 transcrip-
tion factor is restricted to stem cells within the basal
layer of squamous epithelia. Consequently, complete de-
letion of p63 in mice leads to an absence of squamous
epithelia and their derivatives, such as hair, teeth, and
mammary, lacrimal, and salivary glands. Moreover,
limbs are severely truncated, which illustrates the utmost
importance of functional ectoderm for limb bud initia-
tion and patterning. Without p63, no AER is formed,
and the mesenchymal cells of the limb bud degenerate,
most likely because of a lack of FGF8 (Yang et al. 1999).
The human ectrodactyly disorders cannot simply be
explained by a loss of p63 function. Even though almost
all EEC mutations affect arginine residues in the DNA-
binding domain, this does not necessarily entail a total
loss of function, since p63 still can interact and thus
inﬂuence other proteins via its SAM domain. Mutations
in this domain, on the other hand, cause Hay-Wells
syndrome (MIM 106260), which comprises only minor
limb abnormalities. How exactly the changed DNA-
binding capacity of p63 leads to a degeneration of only
the central part of the AER to cause splitting of the
autopod needs to be determined.
Another form of ectrodactyly has been linked to de-
letions on chromosome 7q (SHFM1 [MIM 183600]).
This region contains two homeobox genes, DLX5 and
DLX6. The deletion of both genes in the mouse results
in an SHFM-like phenotype.
Other absence defects involve either the radial or the
ulnar ray of the limb. Holt-Oram syndrome (HOS [MIM
142900]) is characterized by the combination of radial
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ray defects, such as hypoplasia/aplasia of the thumb and
aplasia of the entire radius, with congenital heart defects.
The responsible gene,TBX5, belongs to the T-box family
of transcription factors, which are crucial for, among
other functions, mammalian limb development and iden-
tity (Basson et al. 1997). Interestingly, Okihiro syndrome
(MIM 607343), which combines features of TBS and
HOS, has recently been linked to mutations in SALL4,
a homolog of SALL1, raising questions as to an inter-
action of TBX5 and SALL transcription factors (Kohl-
hase et al. 2002). Congruent with the localization of the
human malformations, Tbx5 is expressed exclusively
within the murine forelimb, whereas the related Tbx4
is constricted to the hindlimb. It is tempting to speculate
that the T-box code has a function similar to that of the
Hox code, in that it determines body-part identity.
Tbx5/ mice die in utero because of severe heart mal-
formation before limb development is sufﬁciently ad-
vanced to assess limb identity. Human mutations are
known that predominantly cause cardiac defects. For
some of these, a differential impairment of binding to
cardiac-speciﬁc promoters has been demonstrated (Bas-
son et al. 1999).
Loss-of-function mutations in TBX3, which is active
in the forelimb and hindlimb, are known to cause the
dominant ulnar-mammary syndrome (MIM 181450)
(Bamshad et al. 1997). The limb malformations affect
primarily posterior structures—that is, the third to ﬁfth
digits and the ulna, which may be hypoplastic or de-
formed. A postaxial polydactyly can be also observed,
and the fourth and ﬁfth toe are frequently shortened.
Tbx3 has been shown to be expressed in an anterior and
a posterior stripe in the limb bud. The posterior stripe,
which seemingly conﬁnes identity of the posterior digits,
appears to be independent of ZPA signaling, whereas
the anterior expression domain is sensitive to Bmp2 and
Shh and is thought to determine the width of the bud
(Tumpel et al. 2002).
Acheiropodia (MIM 200500) is a rare recessive con-
dition with severe truncation defects of the upper and
lower extremities and aplasia of the hands and feet. The
limb phenotype somewhat resembles that of Shh/mice,
indicating a possible involvement of the hedgehog path-
way. A deletion in the human ortholog of the mouse
Lmbr1 gene was identiﬁed that removes intronic se-
quence as well as exon 4, resulting in a presumably in-
active truncated protein (Ianakiev et al. 2001).
Disorders of Dorsoventral Pattering
Nail-patella syndrome (NPS [MIM 161200]) is an ex-
ample of a disturbed patterning along the dorsoventral
axis. Characteristic ﬁndings are dysplastic nails and hy-
poplastic or aplastic patellae, together with iliac horns.
Abnormalities of the elbows and nephropathy are as-
sociated manifestations. After evidence for linkage of the
condition to 9q31 had already emerged, the similar phe-
notype of the corresponding knockout mouse led to the
discovery of mutations in LMX1B (Chen et al. 1998;
Dreyer et al. 1998). The associated nephropathy stems
from an altered expression of type IV collagen at the
glomerular basement membrane, leading to defects in
podocyte differentiation. Lmx1b was shown to regulate
the expression of this collagen (Morello et al. 2001).
The pathomechanism underlyingNPS appears to be hap-
loinsufﬁciency (Dreyer et al. 2000).
Disorders Involving HOX Genes
The ﬁrst human disorder discovered to be caused by
a HOX gene mutation was synpolydactyly (SPD [MIM
186000]). Its hallmark is a dominantly inherited syn-
dactyly between the third and fourth ﬁnger and the
fourth and ﬁfth toe. Additional features include clino-
dactyly, camptodactyly, and brachydactyly of the ﬁfth
ﬁnger, as well as syndactyly and brachydactyly of the
second to the ﬁfth toes. The genetic cause is an expansion
of an imperfect polyalanine coding repeat in exon 1 of
HOXD13 (Muragaki et al. 1996). The normally occur-
ring 15 alanine residues in the N-terminal part of
HOXD13 are expanded by 7–14 alanines in affected
cases. In contrast to other repeat-expansion diseases, the
repeat number is meiotically stable across generations.
Repeat length positively correlates with severity and pen-
etrance of the disorder (Goodman et al. 1997). Individ-
uals in whom the longest repeat, 29 residues in total,
was identiﬁed show additional malformations of the
thumb and hallux and extraskeletal defects like hypo-
spadia. An even more pronounced phenotype, with se-
vere brachydactyly and oligodactyly of the feet, was ob-
served in individuals who are homozygous for the
mutation (Muragaki et al. 1996). A much weaker phe-
notype results from deletion mutations that lead to
frameshift and truncation of the protein or a missense
mutation of a conserved residue (Goodman et al. 1998).
Only few mutation carriers have the typical SPD fea-
tures; instead, the second metatarsals can be duplicat-
ed, and the middle phalanges of the toes are slightly
hypoplastic.
Interestingly, mice with inactivated Hoxd13 alleles
show a very mild phenotype without polydactyly (Dolle
et al. 1993; Davis and Capecchi 1996), indicating that
the SPD mutations are not simple loss-of-function mu-
tations. The synpolydactyly homologue (spdh)mousemu-
tant has the SPD phenotype and a polyalanine expansion
similar to the human mutation (Bruneau et al. 2001). The
spdh phenotype closely resembles that of mice with de-
letions of theHoxd11, Hoxd12, andHoxd13 genes (Zak-
any and Duboule 1996), raising the possibility that the
alanine expansions interfere with other limb-expressed
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Hox genes. Further interesting ﬁndings are that, in spdh
homozygotes, the proliferation of the autopod chondro-
cytes is reduced and that 5′ Hox genes are expressed in
the perichondrium after birth. In addition to patterning,
Hox genes apparently have a function in the regulation
of growth (Albrecht et al. 2002).
Hoxa13 is expressed in the distal limb bud, similar to
Hoxd13. Heterozygous mutations in theHOXA13 gene
are the cause of hand-foot-genital syndrome (MIM
140000), a condition characterized by short ﬁrst meta-
carpals, hypoplastic distal phalanges of the thumb and
toes, and urogenital abnormalities such as duplications
of the female urogenital tract, malpositioning of the ure-
teral oriﬁces, and hypospasias of varying degrees in af-
fected males (Mortlock and Innis 1997). Most disease-
causing mutations identiﬁed so far are nonsense
mutations, which can be assumed to lead to a complete
loss of function. Interestingly, an expansion of the poly-
alanine stretch at the N-terminus leads to an identical
phenotype (Utsch et al. 2002). Hence, alanine expan-
sions in HOXA13 produce loss of function, whereas
similar expansions in the related HOXD13 have com-
plex effects.
Mutations in HOXA11 have recently been shown to
cause amegakaryocytic thrombocytopenia and radioul-
nar synostosis (MIM 605432) (Thompson and Nguyen
2000). The site of the malformation reﬂects the devel-
opmental expression of HOXA11. The mutations are
single-base-pair deletions that are thought to cause a
premature stop codon by frameshift, thus truncating the
protein within the homeodomain. A loss of function is
therefore likely.
Disorders of Early Differentiation
Pattern formation is the process during which number,
size, and shape of the cartilaginous template are delin-
eated. Once the pattern is determined, cells migrate to
the sites of future skeletogenesis and form condensations
that anticipate the structure of the skeleton (anlage). Ex-
tracellular matrix molecules such as versican, tenascin,
syndecan, heparan sulfate, and chondroitin sulfate pro-
teoglycans are highly expressed in these cells and con-
tribute to the “sticky” nature of the cell aggregates. The
next step is the overt differentiation of these cells into
cartilage-forming chondrocytes in endochondral skeletal
elements or into bone-forming osteoblasts in membra-
nous skeletal elements.
In areas of endochondral bone formation, the con-
densed cells differentiate into chondrocytes. The tran-
scription factor Sox9 has been shown to be essential for
this process (Bi et al. 1999). Sox9 is a member of the
Sox family of transcription factors, which are character-
ized by a high-mobility group–box DNA-binding do-
main. It is expressed in the early cartilaginous conden-
sations and, at later stages, in growth-plate chondrocytes.
One of its regulatory targets isCol2a1, the gene encoding
the major collagen in cartilage; Sox9 binds speciﬁcally to
sequences within the ﬁrst intron of this gene (Lefebvre et
al. 1998). Two other members of the Sox family, Sox5
and Sox6, are also required for overt chondrocyte dif-
ferentiation. Homozygous Sox5/ mutant mice and
Sox6/ mutant mice are born with relatively mild skel-
etal anomalies. In contrast, Sox5/Sox6 double homozy-
gous mice die in utero because of severe defects in car-
tilage formation. A detailed analysis has shown that Sox9
is needed for the formation of mesenchymal condensa-
tions, whereas Sox5 and Sox6 are required for the dif-
ferentiation of condensed cells into chondrocytes (Aki-
yama et al. 2002).
The transforming growth factor b (Tgfb)/bone mor-
phogenetic protein (BMP)/GDF5 pathway plays an
important role in the regulation of condensation and dif-
ferentiation of precursor cells into chondrocytes. Signal-
ing of the Tgfb superfamily members requires the binding
of the ligand to cell-surface receptors consisting of two
types of transmembrane serine/threonine kinase recep-
tors, classiﬁed as type I and type II. The type II receptor
transphosphorylates and thus activates the type I recep-
tor. The intracellular substrates of the activated type I
receptors are the Smads. Smads 1, 5, and 8 are phos-
phorylated and then translocated to the nucleus, where
they participate in the transcriptional regulation of genes
involved in cartilage and bone formation (Massague and
Chen 2000; Miyazono et al. 2001). Overexpression of
Bmp2 or Bmp4 in chick embryos is followed by dramatic
increases in both the size and shape of skeletal elements.
Similar effects can be observed by overexpressing a con-
stitutively active BmpRIb, whereas the opposite effect is
achieved by expressing a dominant negative truncated
form of the receptor (Zou et al. 1997). The likely mech-
anism is the recruitment of mesenchymal precursor cells
to the cartilage condensations and to the perichondria,
which contribute cells to the anlage by appositional
growth. Recruitment of cells to condensations is al-
so consistent with the known action of BMPs and
Gdf5 to induce cartilage and bone when implanted
ectopically.
In areas of membranous bone formation, the con-
densed cells differentiate into osteoblasts, which pro-
duce bone matrix. Genetic experiments in mice have
demonstrated that Cbfa1/Runx2 is essential for this pro-
cess (Otto et al. 1997). Runx2 is a member of a small
family of transcription factors that are homologous to
the Drosophila runt gene. In Runx2 null mice, no en-
dochondral or membranous bone is formed, because of
an arrest during the early steps of osteoblast differen-
tiation. Recently, a Cbfb-deﬁcient mouse model with a
similar yet less severe phenotype made clear that Runx2
directly interacts with Cbfb to fulﬁll its role. A direct
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interaction of both proteins was shown (Kundu et al.
2002). Osterix, another transcription factor, is thought
to act downstream of Runx2 (Nakashima et al. 2002).
Mesenchymal condensations resemble the future skel-
eton in shape and size. In many instances, though, more
than one bone or cartilage can arise from a single con-
densation. This is particularly evident in the limbs. The
digital rays are thought to be formed from prechon-
drogenic condensations that appear spatially continu-
ous and subsequently segment into individual skeletal
elements. Morphologically, development of most joints
begins with a condensation of cells at the future joints
and the repression of chondrogenesis at these sites. In
the chick, this so-called “interzone” develops into a
three-layered structure, with the central region under-
going apoptosis resulting in the formation of the joint
cavity. Recently, a member from the Wnt family,
Wnt14a, has been implicated in joint induction (Hart-
mann and Tabin 2001).Members of the BMP/GDF fam-
ilies are expressed in the joint interspace and have also
been reported to be involved in joint formation (Francis-
West et al. 1999). Among them, Gdf5 is the most prom-
inent. Inactivation of Gdf5, as observed in the brachy-
podism mutation, results in the loss of interphalangeal
joints. Multiple other genes involved in the regulation
of chondrogenesis can be expected to play a role in this
process. Overexpression of Runx2, for example, which
is normally not expressed in the joint region, results in
the lack of a morphologically deﬁned interzone and
missing Gdf5 expression, indicating that it interacts
with the early events of joint formation (Stricker et al.
2002).
Genetic defects that result in the disturbance of mes-
enchymal condensation and/or differentiation can be
expected to have a patterning-like phenotype—that is,
loss or underdevelopment of certain bones, together
with a growth defect. Such conditions have been termed
“dysostoplasias,” indicating that aspects of dysostosis
occur together with those of the dysplasias (Mundlos
and Olsen 2002). Conditions that ﬁt into this category
can be found among the brachydactylies and other syn-
dromes affecting early bone development.
Brachydactyly Types A, B, and C
Brachydactyly (from the Greek brachys, meaning
“short,” and daktylos, meaning “digit”) is “shortening
of the digits due to anomalous development of any of
the contributing phalanges or metacarpals of which they
consist” (Bell 1951, p. 2). Brachydactylies have been
classiﬁed, on anatomic and genetic bases, into ﬁve
groups, A to E, including three subgroups (A1, A2, A3)
that usually manifest as autosomal dominant traits.
Brachydactyly type A1 (BDA1 [MIM 112500]) is
characterized by hypoplastic/aplastic middle phalanges.
Interestingly, BDA1 was the ﬁrst human condition rec-
ognized to be inherited in a dominant fashion. Named
after this landmark paper, it is also called “Farabee-type
brachydactyly.” BDA1 was recently shown to be caused
by heterozygous missense mutations in the amino-ter-
minal domain of the signaling molecule Indian hedgehog
(IHH) (Gao et al. 2001). The role of Ihh during early
digit formation is not well understood, and mice with
one inactivated Ihh allele do not show a brachydactyly
phenotype. Homozygous inactivation results in a severe
and lethal chondrodysplasia characterized by the ab-
sence of cortical bone, reduced proliferation and ab-
normal differentiation of chondrocytes, and defects in
joint formation (St-Jacques et al. 1999). The pivotal role
of this signaling molecule in chondrocyte differentiation
is discussed in the “Disorders of Growth” section.
Brachydactyly type B (BDB [MIM 113000]) is char-
acterized by hypoplasia/aplasia of the distal phalanges
and/or nails. The thumb is usually unaffected but may
be duplicated in severe cases. Symphalangism, espe-
cially of the interdigital joints, occurs. BDB is caused
by truncating mutations located in two distinct regions
of the receptor tyrosine kinase ROR2 (Oldridge et al.
2000). The truncations distal to the tyrosine kinase
domain are associated with a more severe phenotype
than are proximal mutations, which disrupt or delete
this entire domain (Schwabe et al. 2000). Ror2 has a
pivotal role in chondrocyte differentiation, as demon-
strated by the severe and lethal chondrodysplasia ob-
served in Ror2 null mice (Takeuchi et al. 2000). How-
ever, the mechanism explaining the brachydactyly
phenotype remains unclear.
Brachydactyly type C (BDC [MIM 113100]) is char-
acterized by brachymesophalangy of the second, third,
and ﬁfth ﬁngers, sometimes together with hyperpha-
langy, usually of the second and third ﬁngers, and short-
ening of the ﬁrst metacarpal. As a rule, the fourth ﬁnger
is not affected and is therefore the longest digit in BDC.
Heterozygous frameshift or nonsense mutations affect-
ing GDF5, also called “cartilage-derived morphogenetic
protein 1” (CDMP1), have been identiﬁed in several in-
dividuals with BDC (Polinkovsky et al. 1997). Homo-
zygous mutations located within the active domain of
GDF5 lead to severe disturbance of limb morphogenesis
in acromesomelic chondrodysplasias of the Grebe (MIM
200700) (Thomas et al. 1997) and Hunter-Thompson
(MIM 201250) (Thomas et al. 1996) types, as well as
Du Pan syndrome (MIM 228900) (Faiyaz-Ul-Haque et
al. 2002).
Defects of Joint Formation
Abnormalities in joint formation occur in several ge-
netic conditions. Patients with proximal symphalangism
(MIM 185800) show fusion/malformation of the prox-
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Figure 3 Campomelic dysplasia in a stillborn fetus. Note the
hallmarks of the disorder: bowing of femora and tibiae, hypoplasia of
scapulae and pelvis, and a small, bell-shaped thorax with a decreased
number of ribs. SOX9 mutations cause a defective formation of early
condensations that precede the formation of a cartilaginous skeleton.
imal interdigital joints together with deafness due to an
ankylosis of the stapes within the middle ear. Multiple-
synostosis syndrome (MIM 186500), a more severe form
of this condition, was later shown to be allelic. Hetero-
zygous mutations affecting the Bmp antagonist noggin
(NOG) (Gong et al. 1999; Marcelino et al. 2001) were
shown to be the cause of these conditions.
Campomelic Dysplasia
Campomelic dysplasia (MIM 114290) is a dominant
disorder caused by haploinsufﬁciency of the transcrip-
tion factor SOX9 (Wagner et al. 1994). The phenotypic
abnormalities include (i) bowing and angulation of long
bones, (ii) hypoplasia of the scapula and pelvis, (iii) ab-
normalities of the vertebral column with a decreased
number of ribs, and (iv) craniofacial abnormalities (cleft
palate, micrognathia, hypertelorism, and a ﬂat facies)
(ﬁg. 3). Most affected babies die, in the neonatal period
or during early infancy, of respiratory distress caused by
a small rib cage, narrow airways (defective tracheo-
bronchial cartilage), and hypoplastic lungs. However,
long-term survivors have been described. Three-quarters
of the cases with a male karyotype have a complete or
partial sex reversal. Other tissues affected include kid-
ney, heart, brain, and pancreas, consistent with the ex-
pression pattern of Sox9 in the developing mouse.
Four major classes of mutations causing campomelic
dysplasia have been reported. The missense mutations
impair DNA binding, a ﬁnding that is consistent with a
loss-of-function model. The truncating mutations reduce
transactivation activity and thereby impede the ability
of SOX9 to activate target genes. SOX9 has a large 5′
regulatory region, and translocations or deletions in this
area apparently interfere with normal SOX regulation
(Meyer et al. 1997).
Ellis–van Creveld Syndrome
Ellis–van Creveld syndrome (MIM 225500) is also
referred to as “chondroectodermal dysplasia.” It is a
recessive disorder, and—as the designation implies—the
clinical features are a combination of skeletal and ec-
todermal abnormalities. The major features consist of
(i) short stature, of prenatal onset, that is most pro-
nounced in the distal segments; (ii) skeletal defects, in-
cluding polydactyly, short and broad middle phalanges
and hypoplastic distal phalanges, fusion of wrist bones,
an abnormal pelvis, a narrow thorax with thin ribs, and
hypoplasia of the upper lateral tibia; (iii) hypoplastic
ﬁngernails; (iv) cardiac defects; (v) neonatal teeth, or
small teeth with delayed eruption; and (vi) a frenulum
from the alveolar ridge to the upper lip, as well as defects
in the alveolar ridge. The responsible gene, called EVC,
was mapped in an Amish pedigree and encodes a
992–amino acid protein of unknown function contain-
ing a leucine zipper motif and nuclear localization signals
(Ruiz-Perez et al. 2000).
Cleidocranial Dysplasia
Cleidocranial dysplasia (CCD [MIM 119600]) is a
dominantly inherited disorder caused by mutations in
CBFA1/RUNX2 (Mundlos et al. 1997). CCD is char-
acterized by (i) hypoplasia/aplasia of the clavicles; (ii)
delayed ossiﬁcation of cranial sutures and fontanelles;
(iii) dental anomalies, including delayed eruption of de-
ciduous and permanent teeth and supernumerary teeth
of the permanent dentition; and (iv) short stature. A
number of other skeletal abnormalities are commonly
observed, including a narrow, bell-shaped thorax; cer-
vical or missing ribs; and characteristic changes in the
pelvis, consisting of hypoplastic iliac wings and a wide
symphysis pubis. Large femoral epiphyses, two ossiﬁ-
cation centers of the second metacarpal, and a short
middle phalanx of the ﬁfth ﬁnger are frequently found.
The bone development is generally retarded. The face
and the skull have a characteristic appearance, with a
relatively large cranium, frontal and parietal bossing,
and a frontal groove originating from ossiﬁcation defects
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within the metopic suture. The nose is short and ante-
verted, and the maxilla is hypoplastic, giving the im-
pression of a relative prognathism (Mundlos 1999).
CCD is caused by haploinsufﬁciency of Runx2. The
mutations identiﬁed so far include deletions of the entire
gene and ﬂanking regions; nonsense mutations and
frame shifts, which can be expected to result in RNA
degradation; and missense mutations in the DNA bind-
ing domain, which were shown to interfere with DNA
binding (Quack et al. 1999; Otto et al. 2002). Interest-
ingly, some of the truncating mutations that may result
in stable proteins were shown to delete binding sites for
Smad. A missense mutation affecting serine 104 was
shown to interfere with heterodimerization of Runx2,
thereby mimicking the inhibitory effect of phosphory-
lation of this residue (Wee et al. 2002).
CCD is a typical condition that combines features of
a dysostosis—that is, abnormal patterning (aplasia of
clavicles and supernumerary teeth)—with those of a
skeletal dysplasia affecting the skeleton as a whole (short
stature). This combination of defects can be explained
by the dual role of Runx2 in skeletal development. First,
it is essential for the differentiation of osteoblasts by
tightly controlling a number of downstream genes. This
control appears to be exquisitely dose sensitive, since
even a 50% reduction is sufﬁcient to produce a phe-
notype. Runx2/ mice are a good model for CCD, since
they recapitulate most of the human phenotype (with
the exception of supernumerary teeth) (Otto et al. 1997).
The skull phenotype can be explained by a reduced rate
of differentiation of precursor cells into osteoblasts at
the site of bone growth—that is, the suture lines. The
clavicles are hypoplastic, with delayed endochondral os-
siﬁcation of the medial part and absent intramembran-
ous formation of the lateral part (Huang et al. 1997).
A second role for Runx2 is in the regulation of chon-
drocyte hypertrophy and the invasion process, which
explains the delay in bone maturation and the short
stature observed in patients with CCD (Kim et al. 1999).
Furthermore, Runx2 appears to have a role beyond em-
bryonic development. Some individuals with CCD have
very low bone density and suffer from osteoporotic frac-
tures (Quack et al. 1999; Morava et al. 2002; Unger et
al. 2002). Whether this is caused by the downregulation
of downstream genes such as alkaline phosphatase or
by a reduced osteoblast differentiation remains to be
determined.
Leri-Weill Dyschondrosteosis and Langer Mesomelic
Dysplasia
Leri-Weill dyschondrosteosis (LWD [MIM 127300])
and Langer mesomelic dysplasia (MIM 249700) are
caused by mutations in the short stature homeobox gene
(SHOX) (Belin et al. 1998; Stuppia et al. 1999; Clement-
Jones et al. 2000; Zinn et al. 2002). It resides within the
pseudoautosomal regions on the X and Y chromosomes
and may also play a role in nonsyndromic short stature
and in Turner syndrome. LWD is caused by haploin-
sufﬁciency, whereas Langer mesomelic dysplasia is due
to homozygous loss-of-functionmutations. LWD is char-
acterized by short stature, Madelung deformity of the
forearm, and limited motion at the elbow. Langer me-
somelic dysplasia results in a rudimentary ﬁbula, a very
short dysplastic tibia, a distally reduced ulna, and a
bowed shortened radius. Additional features are short
ﬁngers, broad hands, and hypoplastic mandibles. The
target genes and the exact role of SHOX are unknown.
The combination of symptoms, however, suggests a role
in early chondrocyte differentiation as well as in the
growth plate.
Disorders of Growth
In contrast to the bones of the skull that are formed by
a direct transformation of mesenchymal cells into os-
teoblasts, so-called “desmal ossiﬁcation,” the major part
of the skeleton is formed by endochondral ossiﬁcation.
In endochondral ossiﬁcation, a cartilaginous template is
formed ﬁrst, which is subsequently replaced by bone.
Central to this process is the formation of a growth plate,
a highly organized structure that generates all of the
longitudinal growth (ﬁg. 4). Growth-plate chondrocytes
are invariably arranged in three layers: reserve chon-
drocytes, proliferating chondrocytes, and hypertrophic
chondrocytes. A very complex interplay of different sig-
naling pathways regulates the rate of proliferation and
the conversion of proliferating chondrocytes into hy-
pertrophic chondrocytes. During the process of chon-
drocyte differentiation, the matrix composition changes
dramatically through the production of other compo-
nents, such as collagen type X; the expression of me-
talloproteinases; and calciﬁcation. At the same time,
blood vessels begin to penetrate the calciﬁed cartilage,
bringing in osteoclasts, which remove cartilage, and os-
teoblasts, which build new bone. With further growth,
the central and primary center of ossiﬁcation expands
toward the ends of the bones, and secondary centers of
ossiﬁcation form within the cartilage remnants. The
growth plate, now localized between the epiphysis (the
secondary center of ossiﬁcation) and the metaphysis (the
distal end of former primary ossiﬁcation center), remains
active until the end of puberty, when primary and sec-
ondary ossiﬁcation centers fuse. At this point, the car-
tilage of the joints is the only cartilage that remains of
the former anlage.
Growth hormone secreted by the pituitary gland and
IGF1 produced by proliferating and hypertrophic chon-
drocytes, among many other tissues, act largely indepen-
dently to control the rate of chondrocyte proliferation.
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Figure 4 Chondrocyte differentiation and proliferation in the growth plate. Chondrocytes are arranged in four layers, representing their
stages of differentiation: (i) resting, (ii) proliferating, (iii) prehypertrophic, and (iv) hypertrophic/terminal hypertrophic chondrocytes. The latter
are replaced by bone by the joint action of osteoblasts (green) and multinuclear osteoclasts (blue). Genes that are characteristically expressed
within each layer are listed on the right side. A complex signaling network regulates proliferation and differentiation of chondrocytes. Prehy-
pertrophic chondrocytes express Ihh, which regulates PTHrP, which is expressed in the joint region, via the perichondrium. PTHrP, in turn,
inhibits differentiation of proliferating chondrocytes. FGFs inhibit chondrocyte proliferation and stimulate their differentiation. BMPs act
antagonistically to the FGFs. The intensity of gray shading indicates the degree of calciﬁcation of the extracellular matrix.
Disorders affecting this pathway result in proportionate
dwarﬁsm without much skeletal dysplasia, suggesting
that they are major regulators of linear bone growth and,
thus, of body size. The vast majority of other short-stat-
ure disorders, however, result in disproportionate dwarf-
ism, presumably because they affect not only prolifera-
tion but also differentiation of chondrocytes.
Two major signaling pathways that control prolif-
eration and differentiation of chondrocytes have been
identiﬁed: the Ihh/parathyroid hormone (PTH)–related
peptide (PTHrP) pathway and the FGF pathway. Ihh,
the second mammalian hedgehog ortholog, plays a cen-
tral role in the regulation of chondrocyte proliferation
and hypertrophy. Ihh signals through the HH pathway
(also see the “Disorders of Skeletal Patterning” section).
Ihh appears to have direct and indirect functions.
Through a yet-unknown cascade of events, Ihh indi-
rectly regulates the expression of PTHrP, which is nor-
mally expressed in chondrocytes close to the joint sur-
face. PTHrP is a secreted molecule transducing its signal
via the PTH/PTHrP receptor (PPR) and plays a critical
role in the regulation of chondrocyte hypertrophy by
keeping cells in the nonhypertrophic proliferative state.
Ihh and PTHrP form a feedback loop whereby Ihh up-
regulates the synthesis of PTHrP, thereby indirectly
slowing down the process of chondrocyte hypertrophy
(Vortkamp et al. 1996).
FGF signaling plays a major role in the regulation of
chondrocyte proliferation and differentiation.More than
20 different FGFs are currently known, and splice vari-
ants further widen the diversity. They are involved in a
multitude of developmental and physiological processes,
act as potent mitogens for chondrocytes as well as for
osteoblasts, and stimulate bone formation in vitro and
in vivo. The four distinct FGF receptors (FGFRs) are
activated by most members of the FGF family. Activity
and speciﬁcity of the FGF/FGFR complex is dependent
on the tissue-speciﬁc expression of splice variants and the
composition of the extracellular matrix (ECM), which
binds FGFs and is an indispensable cofactor for activa-
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tion of the FGF receptors. Only few downstream targets
of FGFRs have been elucidated, among them PLCg, Shc,
MAP kinase, and the transcription factor STAT1. FGFR1
and FGFR3 are both expressed in the growth plate. Their
distinct domains of expression (FGFR3 is expressed in
proliferating chondrocytes, whereas FGFR1 is expressed
in prehypertrophic and hypertrophic chondrocytes) sug-
gest unique functions. Inactivation of Fgfr3 in the mouse
results in overgrowth of the long bones, whereas ex-
pression of an activating mutation results in dwarﬁsm,
indicating that Fgfr3 functions as a regulator of chon-
drocyte proliferation and/or hypertrophy (for a review
of FGF function see Ornitz and Marie 2002). It is not
yet clear which of the many different FGFs expressed in
the developing endochondral bone is the predominant
ligand for FGFR3 at the growth plate. However, the sim-
ilarity between the phenotype of a recently created Fgf18
knockout and the Fgfr3-deﬁcient mouse model indicates
that it may be Fgf18 that rules the growth plate in com-
petition with its opponents, the BMPs (Liu et al. 2002).
The Ihh/PTHrP and the FGF signaling pathways also
interact with members of the BMP family. At the growth
plate, FGFs have been shown to antagonize BMP action
by inhibiting Ihh expression and to decrease chondro-
cyte proliferation by accelerating chondrocyte hyper-
trophy (Minina et al. 2002).
The next and ﬁnal step in endochondral bone for-
mation is the replacement of hypertrophic cartilage by
bone. This requires vascular invasion, a step initiated and
controlled by an interaction of antiangiogenic and an-
giogenic factors. To stimulate vessel invasion from the
bone collar, the hypertrophic chondrocytes express vas-
cular endothelial growth factor (VEGF). As pointed out
in the “Disorders of Early Differentiation” section,
Runx2 is a transcription factor of pivotal importance for
bone formation. In cartilage, Runx2 is expressed in non-
proliferative and prehypertrophic chondrocytes (Stricker
et al. 2002), one of its target genes being VEGF (Zelzer
et al. 2001). If Runx2 is expressed speciﬁcally in non-
hypertrophic chondrocytes in Runx2/ mice, it is able
to partially rescue the differentiation defect and induces
chondrocyte hypertrophy and endochondral ossiﬁcation
(Takeda et al. 2001). Furthermore, despite the absence
of osteoblasts in rescued animals, osteoclasts resorbing
the cartilage matrix were identiﬁed. Hence, Runx2 seems
to induce chondrocyte hypertrophy and the consecutive
removal of calciﬁed cartilage in parallel with its key func-
tion in osteoblast differentiation. VEGF is not secreted
by the hypertrophic chondrocytes, but it is walled in the
hypertrophic cartilage. As a fascinating regulatory mech-
anism, it was shown to be released by the action of ma-
trix-metalloproteinase-9 (MMP-9), which is produced by
osteoclasts (Vu et al. 1998). The hypertrophic chondro-
cytes furthermore ensure their posthumous removal by
expressing MMP-13, which alone has little proteolytic
activity but is strongly activated by MMP-9 (Engsig et
al. 2000).
Cartilage is characterized by a unique ECM that
accounts for ∼90% of the tissue volume. The main
component is ﬁbrous collagen, which confers tensile
strength. In the resting and proliferating chondrocytes,
production of type II collagen predominates, which can
form ﬁbers together with type IX and type XI collagen.
Type X collagen, in contrast, is speciﬁc to hypertrophic
cartilage. Proteoglycans—above all, aggrecan—are of
high abundance. They are giant molecules with a gel-
like consistency that are composed of a core protein to
which are attached different kinds of glycosaminogly-
cans (GAGs), which are highly sulfated and thus neg-
atively charged. This allows them to bind large amounts
of cations and water molecules and to be mutually re-
pellent, which is thought to contribute to the elasticity
of the cartilage. Glycoproteins are a third group of ma-
trix components, comprising, among others, perlecan,
ﬁbronectin, tenascin, and cartilage oligomeric matrix
protein (COMP). COMP is a pentameric glycoprotein
able to bind calcium at calmodulin-like domains. It
forms noncovalent cross-links by interacting with dif-
ferent types of collagens.
Bone consists mostly of type I collagen. In contrast
to the elastic cartilage, the bone matrix contains few
proteoglycans and instead consists of as much as two-
thirds hydroxyapatite, in order to be rigid.
Disorders Affecting Chondrocyte Differentiation
and Proliferation
Mutations in IHH, one of the key regulators of chon-
drocyte proliferation and differentiation, cause BDA1, as
described in the “Disorders of Early Differentiation” sec-
tion. In addition to hypoplasia/aplasia of the middle pha-
langes, BDA1 is, in some individuals, associated with
short stature, conﬁrming its general role in growth-plate
function (Gao et al. 2001). Ihh is a secreted signaling
molecule that exerts its function over long distances. The
composition of the ECM appears to be of utmost im-
portance for this process, as is demonstrated by the Dro-
sophilamutant tout velu. In these animals, thedistribution
of hedgehog is disorganized by an altered expression of
heparan sulfate (Bellaiche et al. 1998). Loss-of-function
mutations in the EXT genes, the human orthologs of
tout velu, cause multiple cartilaginous exostoses (MIM
133700), a condition characterized by multiple, circum-
scribed, sometimes painful bone protuberances, most fre-
quently located at the ends of tubular bones in close prox-
imity to the growth plates. During adulthood, growth of
the lesions slows, and no new lesions are formed. Addi-
tional dysplastic changes are disproportionate shortening
of the ulna with bowing of the radius and radioulnar or
tibioﬁbular synostosis. Adult height is frequently reduced.
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Malignant degeneration occurs and is caused by second
hits involving other genes. EXT1 is located on chromo-
some 8q24, EXT2 is located on chromosome 11p11-12,
and other loci have also been described. Mutations in
EXT1 cause multiple exostosis and, if involved in a con-
tiguous deletion, are part of tricho-rhino-phalangeal syn-
drome (MIM 190350) (Ludecke et al. 2001).
Several disorders have been described that involve
PTHrP and the PPR. Blomstrand chondrodysplasia (MIM
215045) is characterized by a short-limb–type dwarﬁsm,
with severely shortened tubular bones with club-shaped
ends, an accelerated bone maturation, shortened limbs,
and a generalized sclerosis of bone. Affected children usu-
ally die shortly after birth. The early maturation of the
skeleton is caused by an unhindered chondrocyte hyper-
trophy due to homozygous loss-of-function mutations in
the PPR (Jobert et al. 1998). Dominant activating mu-
tations in the same receptor result in Jansen-type meta-
physeal chondrodysplasia (MIM 156400) (Schipani et al.
1995). Patients suffer from a severe growth retardation
and bone deformations. The joints are enlarged, with os-
seous restriction of mobility and ligamentous hyperlaxity.
Radiologically, there is generalized demineralization (re-
sulting in occasional fractures), rachitiform changes with
enlargement of the metaphyses, and hyperostosis of the
calvarium and the base of the skull. Major laboratory
ﬁndings include hypercalcemia during the ﬁrst months of
life, elevated alkaline phosphatase, and low or normal
serum PTH. Two different missense mutations lead to a
constitutive stimulation of cAMP production by the re-
ceptor, which blocks chondrocyte hypertrophy and hin-
ders the following ossiﬁcation process. Enchondromatosis
(MIM 166000) is characterized by the occurrence of mul-
tiple enchondromas, benign tumors of cartilage that are
usually located in close proximity to or in continuity with
growth plate cartilage. In some cases, a generalized dys-
plasia may be present that is not attributable to the en-
chondromas. Enchondromas can lead to skeletal defor-
mity, and, in rare cases, may result in chondrosarcoma.
A mutant PPR receptor has been identiﬁed in some cases,
which constitutively activates hedgehog signaling. The
mutations can be inherited as germline mutations that
acquire second hits later in life or as somatic mutations
that can be detected only within the lesion (Hopyan et
al. 2002).
The importance of FGF signaling for skeletal growth
ﬁrst became clear when it was discovered that mutations
in FGFR3 lead to achondroplasia (MIM 100800), the
most frequent form of dwarﬁsm (Shiang et al. 1994).
Rhizomelic limb shortening, midface hypoplasia, frontal
bossing, trident hands, and exaggerated lumbar lordosis
are typical of this dominantly inherited condition. The
disproportionately large head may be due to true meg-
encephaly, or, more commonly, it may be due to enlarged
ventricles that are believed to be caused by increased in-
tracranial pressure due to diminished resorption and
drainage of cerebrospinal ﬂuid. The hydrocephalus sta-
bilizes spontaneously in almost all patients (achondro-
plasia-speciﬁc growth curves for head circumference
should therefore be used) and is not related to intellectual
performance, which is normal in individuals with achon-
droplasia. Muscular hypotonia is commonly found in in-
fancy and may be caused by stenosis of the foramen mag-
num. Guidelines for health supervision of children with
achondroplasia can be found in the 1995 AmericanAcad-
emy of Pediatrics (AAP) Guidelines (see the “Health Su-
pervision for Children with Achondroplasia” policy state-
ment, available from the AAP Web site). Mean  SD
adult height is 131 5 cm in males and 124 6 cm in
females. Two allelic disorders exist: Hypochondroplasia
(MIM 146000) is a milder form of the disorder, with less
growth deﬁcit and more or less normal facial develop-
ment. Thanatophoric dysplasia (MIM 187600 and MIM
187601), in contrast, is characterized by severe dispro-
portionate dwarﬁsmwith very short extremities, very nar-
row thorax, and death in early infancy due to respiratory
insufﬁciency. Major radiographic features include severe
platyspondyly, short and relatively broad tubular bones
and bowing of the femora, small facial bones and large
calvaria, and distinct changes of the pelvis. Two types are
differentiated, with type 2 showing straight femora and
craniosynostosis.
All the FGFR3 mutations involved in the three con-
ditions have a receptor-activating effect, thus leading to
ligand-independent tyrosine phosphorylation. The mu-
tations, however, lie in very different regions of the
protein. The most common achondroplasia mutation
(G380R) is located in the transmembrane segment,
whereas hypochondroplasia is most often caused by the
N540K mutation, which modiﬁes a tyrosine kinase do-
main (Shiang et al. 1994; Bellus et al. 1995). Thana-
tophoric dysplasia type 1 is caused, in the great majority
of cases, by an extracellular R248C mutation, whereas
type 2 is generally due to a K650E substitution within
the tyrosine kinase domain of the receptor. For at least
some of these mutations, a correlation between receptor
tyrosine kinase activity and severity of the phenotype
could be shown (Naski et al. 1996). Interestingly, an-
other FGFR3 mutation (P250R) in the extracellular do-
main was identiﬁed in several craniosynostosis cases
(Bellus et al. 1996).
The broad spectrum of FGF action is demonstrated by
autosomal dominant hypophosphatemic rickets (MIM
605380), the only heritable disorder linked to mutations
in an FGF so far. The common rickets phenotype, which
is characterized by a growth defect due to growth-plate
disorganization and mineralization defects, is caused by
a calcium deﬁcit, which leads to an increase of PTH se-
cretion. In hypophosphatemic rickets, however, PTH lev-
els are normal. In contrast, this phenotype is caused by
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an accumulation of FGF23 by mutations, which make it
resistant to inactivation by peptidase cleavage (The
ADHRConsortium 2000).Nearly identical symptomsare
produced by inactivating mutations in the metallopepti-
dase gene PHEX in X-linked hypophosphatemia (The
HYP Consortium 1995). Recent results suggest that
FGF23 is cleaved by PHEX, which explains the close re-
lationship between both forms of rickets (Bowe et al.
2001). Whereas the exact function of FGF23 in growth-
plate chondrocytes and bone cells is only beginning to be
unraveled, it was clearly shown that it downregulates the
sodium-phosphate cotransport in kidney cells, thus caus-
ing the hypophosphatemia of the two disorders.
Another receptor tyrosine kinase implicated in growth
regulation is ROR2, the receptor tyrosine kinase men-
tioned above in connection with BDB. A mouse model
lacking Ror2 shows small but normally shaped limb an-
lagen at early developmental stages but develops mis-
shapen and shortened limbs because of dysregulated en-
dochondral ossiﬁcation. (DeChiara et al. 2000). The
murine phenotype resembles human recessive Robinow
syndrome (MIM 268310), a skeletal dysplasia with (i)
characteristic facial appearance, (ii) chondrodysplasia
with short stature and mesomelic shortening of the
limbs, (iii) hypoplasia of the genitals, (iv) vertebral mal-
formations, and (v) heart defects. In contrast to BDB,
in which two mutational hotspots are located just before
or after the tyrosine kinase coding domain, the muta-
tions in Robinow syndrome are spread throughout the
gene and are expected to result in a loss of function
(Afzal et al. 2000).
Disorders Caused by Defects in Matrix Components
ECM is essential for proper functioning of cartilage
and bone. Most abundant are the collagens, which are
homomeric or heteromeric triple helices of three collagen
chains. Type II collagen is a homomer of three a1 chains
encoded by the COL2A1 gene. A spectrum of different
dominant disorders is linked to this gene, the most del-
eterious being achondrogenesis type II (MIM 200610).
This condition is characterized by (i) very short limbs;
(ii) ﬂat midface, micrognathia, and often cleft palate;
and (iii) hydropic appearance. Radiographically, the ab-
sent or severely retarded ossiﬁcation of the vertebrae,
barrel-shaped thorax, and very short tubular bones with
metaphyseal ﬂare and cupping are most striking. Hy-
pochondrogenesis (MIM 200610) is part of the spectrum
and shows similar but less severe changes. The cause of
both conditions is missense mutations at the C-terminal
end of the helix-forming part of the collagen protein
(Chan et al. 1995). Collagen containing mutant mole-
cules is posttranslationally overmodiﬁed and not se-
creted, resulting in the complete absence of type II col-
lagen from the cartilage matrix (Mundlos et al. 1996).
Spondyloepiphyseal dysplasia congenita (SEDc [MIM
183900]) and Kniest dysplasia (MIM 156550) are
milder forms, the ﬁrst being caused by missense muta-
tions in the C-terminal half of the helix-forming region
and the latter by splice-site mutations, which lead to
small, nontruncating deletions (Spranger et al. 1994).
Both conditions are characterized by disproportionate
short-spine dwarﬁsm with normal-sized hands and feet,
a ﬂat midface, occasional cleft palate, and severe myopia
in ∼50% of cases. Retinal detachment is a common com-
plication. Stickler dysplasia (MIM 120140) represents
the mild end of the collagen type II–related disease spec-
trum. Major clinical ﬁndings are (i) midface hypoplasia;
(ii) cleft palate and Pierre-Robin sequence in infants; (iii)
a high degree of myopia; (iv) sensorineural hearing loss;
(v) normal stature or only mild shortness of stature,
sometimes with Marfanoid appearance; and (vi) joint
pain, morning stiffness, and precocious arthritis. In con-
trast to the more severe forms, Stickler dysplasia is gen-
erally caused by nonsense mutations, resulting in a non-
functional allele, or by mutations in the N-terminal half
of the collagen helix-forming region, preventing the in-
sertion of the molecule into the type II collagen trimer
(Winterpacht et al. 1993).
Collagen type II forms ﬁbrils with other collagens—in
particular, collagen type XI. This biochemical ﬁnding is
mirrored on a genetic basis by mutations in COL11A1
and COL11A2, the two genes encoding the a1 and a2
chains of collagen type XI, in Stickler dysplasia. Other
conditions caused by mutations in collagen type XI are
the recessive and dominant variants of otospondylo-
megaepiphyseal dysplasia (MIM 215150) (Vikkula et al.
1995).
Defective matrix components are also responsible for
the different types of multiple epiphyseal dysplasias
(EDMs) (Briggs and Chapman 2002). Usually beginning
at age 2–10 years, typical symptoms are pain and stiff-
ness in the joints, the knee and the hip beingmost heavily
affected. Osteoarthritis develops in early adulthood.
Body height is normal or sometimes slightly reduced.
Fragmentation and delayed ossiﬁcation of numerous
epiphyses are visible radiographically. The genes under-
lying EDM2 (MIM 600204) and EDM3 (MIM 600969)
are COL9A2 and COL9A3, respectively. A recently re-
ported EDM mutation in COL9A1 completed this list
(Czarny-Ratajczak et al. 2001). All EDM mutations af-
fect splice sites, resulting in mRNAs bearing in-frame
deletions. The cartilage collagen mainly consists of type
II and type XI ﬁbrils. Type IX collagen is restricted to
the surface of the mature collagen ﬁber, which possibly
explains the relatively mild phenotype.
A more severe form of EDM (EDM1 [MIM 132400])
and pseudoachondroplasia (MIM 177170), a condition
characterized by a short-limb dwarﬁsm with body pro-
portions resembling those of achondroplasia but with a
Kornak and Mundlos: Genetic Disorders of the Skeleton 461
normal face, are caused by mutations in cartilage oligo-
meric matrix protein (COMP). Most mutations affect
the calmodulin-like domains, leading to retention of the
misfolded protein in the rough endoplasmatic reticulum.
Since COMP interacts with type I, II, III, and IX col-
lagen, these are also retained within the chondrocytes,
leading to cell death (Thur et al. 2001). Another gene
product associated with EDM (EDM5 [MIM 607078])
is matrilin-3 (MATN3) (Chapman et al. 2001). MATN3
is a matrix protein carrying von Willebrand factor A
domains that appear to interact with COMP and with
type II and type IX collagen (Briggs andChapman 2002).
A recessive form of EDM (EDM4 [MIM 226900])
shows clubfoot, scoliosis, and a double-layered patella as
additional features. Mutations in the diastrophic dyspla-
sia sulfate transporter (DTDST) are underlying this dis-
order (Superti-Furga et al. 1996b). Similar to the type II
collagenopathies, a spectrum of diseases are associated
with mutations in DTDST (Rossi and Superti-Furga
2001). Diastrophic dysplasia (MIM222600), the disorder
in which the transporter was ﬁrst identiﬁed, is a recessive
dwarﬁng condition with a high frequency in Finland
(Hastbacka et al. 1994). This condition is characterized
by (i) multiple joint contractures resulting in therapy-re-
sistant club feet; (ii) proximally set, hypermobile thumbs;
(iii) cystic masses of the external ear (cauliﬂower appear-
ance); (iv) cleft palate; and (v) scoliosis, which is pro-
gressive in most cases. Atelosteogenesis type 2 (MIM
256050) presents with the same pattern of abnormalities
as diastrophic dysplasia but is more severe. Achondro-
genesis type 1B (MIM 600972) represents the most severe
end of the DTDST spectrum, showing hydropic appear-
ance, extreme micromelia, short trunk, absent to severely
retarded ossiﬁcation, and, most characteristically, ex-
tremely short tubular bones with loss of longitudinal
orientation and round or triangular conﬁguration (Su-
perti-Furga et al. 1996a). Asmentioned above, glycosami-
noglycans are not only major matrix components, but,
like heparan sulfate, also important cofactors for FGF
signaling. Inactivation of the sulfate transporter DTDST
results in the production of undersulfated cartilage pro-
teoglycans disturbing growth regulation as well as matrix
integrity. EDM is mostly caused by missense mutations,
as is diastrophic dysplasia. In contrast, stop mutations or
substitutions in transmembrane segments lead to themore
severe phenotypes. A rough correlation between the re-
duction of sulfate transport and disease severity has been
found when mutated DTDST is expressed in Xenopus
oocytes (Karniski 2001).
Perlecan is a heparan sulfate proteoglycan present in
all basement membranes and in cartilage (which does not
have basement membranes). Perlecan is implicated in cell
growth and differentiation through interactions with
growth factors, cell surface receptors, and ECM mole-
cules. Mice with an inactivated perlecan gene (Hspg2/)
develop severe chondrodysplasia (Arikawa-Hirasawa et
al. 1999). Their phenotype somewhat resembles the lethal
autosomal recessive disorder dyssegmental dysplasia, Sil-
verman-Handmaker type (MIM 224410), which led to
the identiﬁcation ofmutations in the human perlecan gene
(Arikawa-Hirasawa et al. 2001). Dyssegmental dysplasia
is a lethal condition with irregularly sized vertebral bodies
that have single or multiple ossiﬁcation centers, small tho-
rax and ribs, and very short, extremely widened tubular
bones. Patients with dyssegmental dysplasia of the Rol-
land-Desbuquois type have similar but less severe changes.
Phenotypic overlapswith Kniest dysplasia exist. Both con-
ditions are caused by insertions and splicing mutations in
the perlecan gene HSPG2 and are predicted to result in
unstable molecules that are not secreted. Furthermore,
structural and functional mutations have been shown to
cause Schwartz-Jampel syndrome (MIM 255800) (Nicole
et al. 2000), a recessive skeletal dysplasia associated with
myotonia. Patients with Schwartz-Jampel syndrome sur-
vive and show much milder phenotypes compared with
the dyssegmental dysplasias, possibly reﬂectingdifferences
in the amount of perlecan in the matrix.
The major component of bone matrix is collagen
type I, which is encoded by two genes, COL1A1 and
COL1A2. Mutations in these genes result in osteogene-
sis imperfecta (OI), or “brittle bone disease” (for review,
see Byers and Cole 2002). OI covers a wide phenotypic
spectrum of conditions characterized by osseous fragility
and fractures. On clinical, genetic, and radiological
grounds, four major subtypes have been delineated. The
most severe cases, classiﬁed as the neonatal type or OI
type II, have (i) a characteristic facial appearance with
dark sclerae and a beaked nose, (ii) an extremely soft
calvarium because of insufﬁcient ossiﬁcation, (iii) short
extremities with bowed legs, and (iv) a small thoracic
cavity. The radiological picture shows a virtual absence
of calvarial mineralization, short and malformed
(“crumpled”) long bones, beaded ribs, and signs of frac-
tures with insufﬁcient healing. Severe nonlethal cases of
the progressive deforming variety are generally diag-
nosed as type III OI. Many of these patients eventually
become wheelchair bound because of the recurrent frac-
tures and poor healing resulting in severe deformity and
instability of the skeleton. Patients with type IV OI show
mild to moderate deformity, short stature, and dentino-
genesis imperfecta. Type I refers to the least severe va-
riety. Affected individuals have blue sclerae, normal
teeth, and normal to near-normal stature, but they have
recurrent fractures that heal without deformity. Very
mild cases of OI may have osteopenia as the only clinical
sign. The majority of cases with OI types II–IV are
caused by mutations, in either COL1A1 or COL1A2,
that replace one of the repetitive glycines within the tri-
ple-helical domain with other, bulkier amino acids. This
disrupts the correct folding of the helix and thus has a
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dominant effect by inactivating a high percentage of the
normal chains as well. Similar to type II collagen, the
less severe phenotype (i.e., type I OI) is caused by non-
sense mutations resulting in mRNA degradation and by
other mutations that result in silent alleles or the exclu-
sion of the mutated protein from the helix. Multiple
subtypes of OI with dominant and recessive inheritance
that are not caused by mutations in either of the collagen
type I genes have been described, expanding the Sillence
classiﬁcation (Cole 2002). Recent studies have shown
that severe cases of OI can be effectively treated with
bisphosphonates, agents that interfere with bone re-
sorption and decrease bone loss in postmenopausal
woman with osteoporosis (Rauch et al. 2002). The treat-
ment appears to selectively inhibit resorption, leaving
bone formation intact.
Disorders of Skeletal Homeostasis
As soon as the ﬁrst bone tissue is formed, osteoclasts/
chondroclasts come into play and start to degrade cal-
ciﬁed cartilage as well as mature bone. This resorptive
activity is a prerequisite for bone growth, since forma-
tion of mature bone tissue is possible only after the re-
moval of calciﬁed cartilage. Proper growth and skeletal
maturation is important to reach an adequate peak bone
mass, which has to be kept stable as long as possible.
On the other hand, it is pivotal that the bone architecture
adjust constantly to changing mechanical and metabolic
needs. Both preservation of overall bone mass and con-
stant restructuring are achieved by a concerted action of
osteoblasts and osteoclasts, called “bone remodeling.”
If remodeling is out of balance, either a loss or an ac-
cumulation of bone occurs, resulting in osteoporotic or
osteopetrotic phenotypes, respectively.
Bone Matrix and Mineralization
Bone consists mostly of type I collagen and hydroxy-
apatite. Osteonectin, bone sialoprotein, and tissue-non-
speciﬁc alkaline phosphatase (TNAP), three of the sev-
eral glycoproteins found in bone, are thought to regulate
hydroxyapatite deposition. Osteoblasts ﬁrst secrete os-
teoid that subsequently calciﬁes in a not completely un-
derstood manner. Hydroxyapatite crystal formation is
inhibited by pyrophosphate (PPi), which is cleaved by
TNAP to phosphate (Pi). This explains why TNAP-de-
ﬁcient mice have a delayed ossiﬁcation and thus reduced
bone growth. Extracellular PPi levels seem to be regu-
lated by the Ank protein, which transports PPi. Osteo-
calcin has, despite what its name suggests, only a minor
effect on bone mineralization but was shown to regulate
cross-linking of other matrix proteins and to inhibit os-
teoblast function. It is one of the few proteins that are
speciﬁcally transcribed by the osteoblast. Some noncol-
lagenous matrix proteins such as vitronectin, osteopon-
tin, and bone sialoprotein contain RGD motifs, which
are recognized by integrins and mediate cell attachment.
Furthermore, bone matrix proteins were shown to bind
to growth factors—for example, Tgfb. Hence, osteo-
blasts and osteoclasts can be regulated in different ways
by interaction with the bone matrix—or can become
dysregulated, in the case of a disturbance of the matrix
components.
Osteoblast Differentiation
Desmal ossiﬁcation and endochondral ossiﬁcation are
dependent on Runx2 activity. Without Runx2, mesen-
chymal precursor cells cannot differentiate into osteo-
blasts. Ihh controls chondrocyte differentiation but is also
essential for osteoblast differentiation, as demonstrated
by the total absence of osteoblasts in long bones of Ihh-
deﬁcient mice (St-Jacques et al. 1999). In Ihh/ mice, the
perichondrium, from which osteoblasts are recruited dur-
ing the endochondral ossiﬁcation process, lacks expres-
sion of Runx2, indicating that Ihh acts upstream of
Runx2. FGF18 also stimulates osteoblast differentiation
and proliferation. It was shown to be expressed in dif-
ferentiating osteoblasts, and FGF18 deﬁciency causes de-
layed ossiﬁcation and osteoblast differentiation (Liu et al.
2002).
Local and Systemic Factors Inﬂuence Osteoblast
Proliferation and Function
LRP5 is a ubiquitously expressed coreceptor for Wnt
growth factors that becomes upregulated during osteo-
blast differentiation and which is inhibited upon binding
to proteins of the Dickkopf (dkk) family. In vitro ex-
periments and data obtained from the analysis of knock-
out mice suggest that it regulates osteoblast proliferation
and function via the canonical pathway involving b-cat-
enin, which is independent of Runx2 (Kato et al. 2002).
Different local factors primarily regulate osteoblast
proliferation and activity. Although BMPs stimulate the
expression of Runx2 in osteoblasts in vitro, their role
in skeletal homeostasis has remained ambiguous, since
their inactivation primarily results in abnormal pattern-
ing. BMP3-deﬁcient mice, however, have a phenotype
compatible with a postdevelopmental function. These
mice have an increased bone density, which is somewhat
unexpected for loss of a “bone inducer” molecule (Dal-
uiski et al. 2001). The amino-terminal (1-34) region of
PTH regulates osteoblast function, through its receptor
PTHR1, in an ambiguous way. Permanent application
stimulates only the early stages of osteoblast prolifera-
tion and suppresses the later stages. Intermittent PTH,
in contrast, increases the numbers of mature, bone-form-
ing osteoblasts (Karaplis and Goltzman 2000). PTH ef-
fects are therefore potentially anabolic and catabolic,
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depending on the dose as well as on the changes of the
dose over time. Sex steroids are crucial for the central
regulation of bone remodeling. The interaction of estro-
gen, androgens, and their different receptors is so com-
plex that it is beyond the scope of this article. In general,
it can be said that estrogen and androgens can, in vitro,
increase bone formation and decrease bone resorption
by reciprocally inﬂuencing osteoblasts and osteoclasts
via direct and indirect pathways (reviewed by Rickard
et al. 1999). Leptin is a hormone that is produced by
adipose tissue and regulates body weight via binding to
hypothalamic receptors. Since it had long been recog-
nized that a high BMI provides protection from osteo-
porosis, the group of G. Karsenty investigated whether
mice deﬁcient for leptin or the leptin receptor would
have abnormal bone density. Both mutants had a two-
to threefold increased bone density, due to an increased
bone formation rate. No direct action of leptin on bone
cells could be detected; instead, intracerebral adminis-
tration of leptin strongly reduced bone density. The sig-
naling from the hypothalamus to the osteoblast was
shown to occur via the sympathetic nervous system and
involved b2-adrenergic receptors (Takeda et al. 2002).
Conditions with Abnormal Mineralization
Abnormal mineralization may present either as under-
mineralization (rachitic changes, osteomalacia) or as ov-
ermineralization (increased density on radiographs, os-
teosclerosis). Hypophosphatasia (MIM 146300, MIM
171760, and MIM 241500) is a characteristic example
of decreased mineralization. Three different types are dis-
tinguished on clinical grounds. The perinatally lethal form
is characterized by (i) lack of ossiﬁcation of calvarial
bones; (ii) short, deformed extremities with absence of
ossiﬁcation of whole bones; (iii) respiratory distress due
to short undermineralized ribs; and (iv) polyhydramnios.
The severe forms are transmitted as autosomal recessive
traits, whereas the late and intermittent forms are usually
dominant. All forms have low or absent serum alkaline
phosphatase levels, resulting frommutations in theTNAP
gene. The cleavage of PPi has been hypothesized to be
central to the function of TNAP in promoting matrix
mineralization. In hypophosphatasia, this enzymatic re-
action cannot take place, and mineralization is inhibited
by high extracellular PPi levels.
Craniometaphyseal dysplasia (CMD [MIM 123000])
is a dominant condition characterized by sclerosis and
overgrowth of cranial bones together with a modulation
defect of the metaphyses. Hyperostosis of calvarial and
facial bones is associated with obstruction of the nasal
cavity, variable compression of cranial nerves, and hy-
pertelorism. The metaphyses of the long bones are dis-
tally broadened, resulting in an Erlenmeyer ﬂask–like
pattern. The condition is caused by speciﬁc mutations
in ANKH (Nu¨rnberg et al. 2001), a gene encoding a
putative multipass transmembrane protein involved in
the intracellular-to-extracellular transport of inorganic
PPi. PPi is the naturally occurring analog of the bis-
phosphonates, known to be inhibitors of mineralization
and bone resorption. It is still unclear how ANKH mu-
tations can result in increased bone formation.
An inactivating mutation in the orthologous Ank was
identiﬁed in the mouse mutant ankylosis (ank), which
shows formation of hydroxyapatite crystals on articular
surfaces and in synovial ﬂuid, progressive arthritis, and
subsequent ankylosis. The ank mutation results in a
lower extracellular concentration of PPi in in vitro ex-
periments (Ho et al. 2000), which may result in aberrant
crystal formation in the joints and induce arthritis. Re-
cently, ANKH mutations, which are located in the trans-
membrane region or which result in alternative start
ATGs, were identiﬁed in selected families with mineral
deposition disease (Pendleton et al. 2002). CMD mu-
tations, in contrast, are located at speciﬁc sites in the
cytosolic portion of the protein, possibly explaining the
completely different phenotypes of the two conditions.
Conditions with Osteoblast Dysfunction
Since Runx2 appears in osteoblasts long before skel-
etal homeostasis is achieved, mutations predominant-
ly have the already-mentioned developmental conse-
quences. Closer observation, though, revealed that CCD
can be associated with osteoporosis (Quack et al. 1999).
Furthermore, severe cases of CCD phenotypically resem-
ble hypophosphatasia (Morava et al. 2002; Unger et al.
2002). The overlap between both phenotypes can pos-
sibly be explained by the fact that expression of alkaline
phosphatase is induced by Runx2.
The genes for recessive osteoporosis-pseudoglioma
syndrome (OPS [MIM 259770]), a dominantly inherited
high-bone-mass trait (HBM [MIM 601884]), and au-
tosomal dominant osteopetrosis type I (ADOI [MIM
166600]) link to the same locus on chromosome 11q13
(Johnson et al. 1997; Van Hul et al. 2002). Several loss-
of-function mutations in low-density lipoprotein (LDL)
receptor–related protein 5 (LRP5) have subsequently
been shown to be causative for OPS. In vitro studies
revealed that the mutations impair Wnt signaling and
stimulation of the osteoblast alkaline phosphatase (Gong
et al. 2001). The pseudoglioma is caused by a persistence
of the hyaloid artery system in the eye that could be
reproduced in Lrp5/mice. In total, seven missensemu-
tations in LRP5 have been shown to be associated with
several slightly differing HBM phenotypes: HBM either
with or without enlarged mandible, which was alter-
natively diagnosed as van Buchem disease, osteopetrosis
type I, endosteal hyperostosis, and autosomal dominant
osteosclerosis (Little et al. 2002; Van Wesenbeeck et al.
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2003). The decisive common feature of all phenotypes,
however, is an increased thickness of long-bone cortices
with high mechanical stability. All mutations are situated
in the ﬁrst extracellular b-propeller module of the LRP5
protein. Several hypercholesterinemia-causingmutations
have been found in the corresponding portion of the
LDL receptor, proving its functional importance for this
protein family. The effect of the ﬁrst identiﬁed HBM
mutation (G171V) is an increase in Wnt signaling, due
to a diminished afﬁnity of LRP5 to the antagonistic pro-
tein dkk, which results in higher osteoblast activity (Boy-
den et al. 2002). The investigation of sclerosteosis (MIM
269500) and van Buchem disease (MIM 239100) prom-
ises to shed light onto the obscure role of BMPs in bone
homeostasis. Both diseases are characterized by an im-
mense bone overgrowth, which leads to osteosclerosis
and tall stature of varying degree. Loss-of-function mu-
tations have been identiﬁed in the SOST gene in scle-
rosteosis. In the milder van Buchem disease, only a 52-
kb deletion downstream of the SOST gene was detected,
which might inﬂuence gene expression. SOST is a homo-
log of Gremlin, a BMP antagonist, and was shown to
block bone formation in vitro (Janssens and Van Hul
2002).
Estrogen loss is the main cause of osteoporosis, a ma-
jor health problem in industrialized countries. Acceler-
ated bone loss during the postmenopausal phase is char-
acterized by reduced osteoblast function and increased
resorption by osteoclasts, whereas the slow decay typical
of osteoporosis at higher ages is mainly due to impaired
osteoblast activity. Mutations in estrogen receptor b and
in the enzyme aromatase, which converts androgens to
estrogen, lead to osteoporotic phenotypes (Smith et al.
1994; Bilezikian et al. 1998). Affected individuals are
usually of tall stature, because of a delay of bone mat-
uration and growth plate closure, which illustrates the
importance of sex hormones for skeletal development.
Cross Talk between Osteoblast and Osteoclast
The model of a balanced competition between osteo-
blasts and osteoclasts in homeostasis predicts that a
weakening of one cell type results in either bone accu-
mulation or bone loss. This is demonstrated by a simple
experiment: A speciﬁc ablation of mature osteoblasts by
transgenic expression of herpes virus thymidine kinase
under control of the osteocalcin promoter causes a gan-
ciclovir-inducible and reversible bone loss, since bone
resorption apparently proceeds normally (Corral et al.
1998). Although osteoblasts and osteoclasts are antag-
onists, they communicate with each other intensively.
This is exempliﬁed by the osteopetrotic (op) mouse mu-
tant, which lacks macrophage-colony stimulating factor
(M-CSF), a soluble growth factor that is produced by
bone stromal cells and promotes proliferation of early
osteoclast precursors (Felix et al. 1990). Yet M-CSF
alone is not sufﬁcient for osteoclast proliferation and
differentiation. RANKL serves as a ligand for the re-
ceptor activator of NF-kB (RANK), a receptor that re-
sides at the cell surface of osteoclast precursors (ﬁg. 5).
RANK initiates osteoclast differentiation via the NF-kB
pathway, involving direct interaction with TRAF6,
which is interconnected with other signaling pathways.
Stromal cells, however, are also able to secrete osteo-
protegerin (OPG), which is a truncated soluble RANK
protein that can bind to RANKL and make it thus in-
accessible to the osteoclast receptor. Whereas RANK
knockouts are severely osteopetrotic, OPG knockouts
are osteoporotic, which highlights the crucial role of this
signaling system for bone remodeling (Simonet et al.
1997; Kong et al. 1999). Most hormonal signals are not
directly received by the osteoclast but are translated by
the osteoblast via M-CSF and RANKL/OPG. An im-
portant exception is calcitonin, which acts directly upon
osteoclasts to stop resorption (Baron et al. 1990). The
other two hormones that regulate calcium homeostasis,
PTH and 1,25-dihydroxyvitamin D3, stimulate RANKL
expression by osteoblasts (Quinn et al. 2001; Thomas
et al. 2001). Interleukin-1 and tumor necrosis factor
(TNF), in contrast, increase M-CSF secretion. This effect
is antagonized by estrogen, which has additionally been
shown to increase OPG production by osteoblasts (Hof-
bauer et al. 1999).
What about feedback from the osteoclast? There is
evidence for production of Tgfb by osteoclasts in re-
sponse to estrogen and androgens (Robinson et al. 1996;
Pederson et al. 1999). Furthermore, Tgfb is bound to
the bone matrix and, in a mechanism similar to the re-
lease of VEGF from the calciﬁed cartilage, osteoclasts
release it by bone resorption. Tgfb stimulates OPG pro-
duction by osteoblasts and osteoblast proliferation, so
that a regulatory negative feedback loop is established
(Takai et al. 1998; Dallas et al. 2002).
Disorders Caused by Disturbed Osteoblast-Osteoclast
Cross Talk
Paget disease of bone (PDB) is a prominent example
of signaling from the osteoclast to the osteoblast. In this
condition, increased bone formation, which leads to cor-
tical thickening, is driven by hyperactive osteoclasts. The
dysregulation can be mimicked by viral infection of
osteoclasts, and intracellular viruslike inclusions are
frequently found in osteoclasts in PDB bone biopsies
(Reddy et al. 2001). Excessive bone formation is pre-
vented by administration of bisphosphonates that are
known to selectively kill osteoclasts. Familial clustering
of PDB suggests a strong genetic component. Indeed,
different chromosomal loci could be linked to the dis-
ease. Evaluation of the candidate gene SQSTM1 on
Kornak and Mundlos: Genetic Disorders of the Skeleton 465
Figure 5 Function and regulation of the osteoclast. Osteoblasts/stromal cells (yellow) regulate proliferation, differentiation, and activity
of the osteoclast via RANKL and M-CSF. M-CSF binds to its receptor, c-fms, on mononuclear osteoclast precursors and stimulates their
proliferation. RANKL stimulates differentiation into multinuclear resorbing osteoclasts via RANK, which transduces the signal with the help
of TRAF6 and NFkB. As soon as the mature osteoclast attaches to the bone surface, it forms a rufﬂed border membrane containing large
amounts of H-ATPase complexes (green) and the chloride channel ClC-7 (red), which together transport HCl and acidify the resorption lacuna.
Protons are provided by the cytosolic carbonic anhydrase type II (CAII). Acidic proteases like cathepsin k (blue circles) become active and
degrade the bone matrix proteins (mainly collagen) and release bound growth factors, above all Tgfb. Tgfb is able to signal back to the osteoblast
establishing a negative feedback loop by stimulating OPG expression. Degradation products are transported out of the cell by transcytosis. Kp
cathepsin k.
chromosome 5q31 revealed several mutations in familial
and sporadic cases of PDB (Hocking et al. 2002; Laurin
et al. 2002). This gene encodes p62 (sequestosome1),
which has been described as a downstream effector of
the RANK/TRAF6 pathway (Sanz et al. 2000). It was
furthermore shown that p62 binds ubiquitin and may
be involved in protein degradation, which could explain
the inclusion bodies seen in pagetic osteoclasts (Geetha
and Wooten 2002).
A similar hereditary disorder with earlier onset is re-
cessive juvenile Paget disease (MIM 239000). It was re-
cently shown either to be caused by a deletion of the
whole OPG-encoding TNFRSF11B gene or by a deletion
of one amino acid in OPG, which prevents it from bind-
ing to RANKL (Cundy et al. 2002; Whyte et al. 2002).
The dominant disorder familial expansile osteolysis
(MIM 174810) is caused by a mutation in the RANK
signaling peptide, which leads to intracellular accumu-
lation and self-stimulation of the receptor (Hughes et al.
2000). Hence, all genes involved in the pathogenesis of
466 Am. J. Hum. Genet. 73:447–474, 2003
PDB and related disorders initially increase osteoclast
activity by a dysregulation of the OPG/RANK/RANKL
system and only secondarily lead to osteoblast stimu-
lation. This is reﬂected by the ﬁnding that the disorders
begin with a phase of increased resorption, which then
entails osteoblast stimulation. As a consequence, ex-
tremely high levels of bone resorption are paralleled by
high levels of bone formation at later stages.
Mutations in TGFB1, which lead to Camurati-En-
gelmann syndrome (MIM 131300), prove the relevance
of the Tgfb feedback mechanism for bone homeostasis
(Janssens et al. 2000; Kinoshita et al. 2000). Bone pain
and walking problems are typical signs of this disorder.
X-rays reveal a fusiform shape and progressive sclerosis
of the long bone diaphyses, due to increased endosteal
and periosteal bone formation. Most mutations are clus-
tered around the disulﬁde bridge between the latency-
associated peptides. The likely pathomechanism is pre-
mature activation of Tgfb.
Another way to disturb the balance between osteo-
blasts and osteoclasts is exempliﬁed by a rare recessive
form of idiopathic osteolysis (MIM 605156). Patients
with this disease have short stature, carpal and tarsal
osteolyses, and an arthropathy, which eventually de-
velops into ankylosis. The underlying genetic cause is
inactivating mutations in matrix-metalloproteinase-2
(MMP-2) (Martignetti et al. 2001). This enzyme is ex-
ceptionally capable of digesting type IV collagen and
is thought to regulate the inﬂammatory response. In
bone, MMP-2 is produced by the osteoclast, but its
function is elusive. A regulatory role has been dis-
cussed—for example, helping to release Tgfb bound to
the matrix or activating other proteases (Dallas et al.
2002). An MMP-2–deﬁcient mouse model lacks a sig-
niﬁcant skeletal pathology and thus corresponds only
weakly to the human phenotype (Narisawa et al. 1997).
Osteoclast Differentiation and Function
The differentiation of the mature, multinucleated os-
teoclast from its mononuclear hematopoietic precursor
occurs in several well-deﬁned steps. First, the formation
of the precursor cells is dependent on PU.1, a hemato-
poietic transcription factor whose disruption in mice
leads to a loss of lymph nodes, macrophages, and os-
teoclasts (Tondravi et al. 1997). Precursor proliferation
is subsequently stimulated by M-CSF, which is produced
by osteoblasts. The fate of these cells critically depends
on Rank-signaling and on the c-Fos transcription factor
(Wang et al. 1992). If either of them is missing, only
macrophages and no osteoclasts develop from themono-
nuclear precursors, resulting in osteopetrotic phenotypes
in mice. The osteoclasts-to-be then fuse and attach to
the bone surface with the help of the vitronectin receptor,
which triggers a signaling cascade involving Pyk2, c-Src,
and c-Cbl to induce the conversion to a polarized re-
sorbing osteoclast. This results in a massive fusion of
acidic vesicles, with the osteoclast plasmamembrane op-
posing the bone surface. The consequent membrane ac-
cumulation creates the so-called “rufﬂed membrane,”
which contains high amounts of v-type H ATPases that
pump protons into the tightly sealed resorption lacunae
between osteoclast and bone surface. Strong extracel-
lular acidiﬁcation is crucial for bone resorption, since
low pH is needed (i) to dissolve the hydroxyapatite of
the bone tissue and (ii) to degrade the organic compo-
nents of the bone matrix—above all, type I colla-
gen—with acidic proteases like cathepsin k (ﬁg. 5). After
cathepsin k has cleaved the collagen ﬁbrils, other pro-
teases come into play that work under less acidic con-
ditions. The degradation products are subsequently
transferred to the basolateral pole of the cell by a trans-
cytosis mechanism (reviewed by Va¨a¨na¨nen et al. 2000).
Disorders Caused by Osteoclast Dysfunction
Changes in bone mass can be caused by reduced bone
resorption due to a malfunction or a reduced number of
osteoclasts. An extreme formof bone accumulation is seen
in osteopetrosis. The majority of human osteopetrosis
cases show high numbers of nonfunctional osteoclasts.
The disease can be phenotypically subdivided into three
(often overlapping) forms, all of which are based on de-
fects in the osteoclast acidiﬁcation machinery. Infantile
malignant osteopetrosis usually begins shortly after birth
and shows autosomal recessive inheritance (ARO [MIM
259700]). Characteristic signs are dense bones without a
regular marrow cavity, bone-within-bone appearance, an
increased fracture rate, hepatosplenomegaly, and cranial-
nerve compression, which can lead to blindness and deaf-
ness (Gerritsen et al. 1994). The disorder is usually lethal
if not treated early by bone-marrow transplantation.Mu-
tations in TCIRG1, which encodes the a3 subunit of the
osteoclast proton pump, are the major cause of recessive
malignant osteopetrosis (Frattini et al. 2000; Kornak et
al. 2000). Different types of mutations in different regions
of the protein have been found in 150% of the cases,
many leading to a truncation. The a subunit is the largest
of the at least 13 subunits that form the v-typeHATPase
and anchors the protein complex to the membrane. Only
one a subunit is present per complex, so that the muta-
tions can only have a loss-of-function effect. No clear
genotype/phenotype correlation has so far been deduced.
An almost indistinguishable osteopetrotic phenotype is
caused by mutations in CLCN7, which encodes the ubiq-
uitously expressedClC-7 chloride channel. It becameclear
that ClC-7 is functionally linked to the H ATPase, since
it resides in the osteoclast rufﬂed membrane and trans-
ports chloride ions in parallel to the protons pumped into
the resorption lacuna (Kornak et al. 2001). A truncating
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Figure 6 Sandwich vertebra in ADOII. ADOII can be diagnosed
by characteristic radiological ﬁndings. The radiograph shows the typ-
ical sandwichlike appearance of the vertebra by thickening of the
endplates.
stop mutation and missense mutations have so far been
identiﬁed in only a minority of cases. In contrast to
TCIRG1mutations, loss of functional ClC-7 inmice leads
to a primary retinal degeneration that has also been de-
scribed in human osteopetrosis cases.
Recently, a splice-site mutation in theGrey-lethal (GL)
gene was found in a single ARO case (Chalhoub et al.
2003). The analysis of the corresponding mouse mutant
indicated that gl, which harbors one putative transmem-
brane segment and is expressed in osteoclasts, osteo-
blasts, skin, and other tissues, might be involved in the
arrangement of the osteoclast cytoskeleton.
A recessive form of intermediate severity is osteope-
trosis with renal tubular acidosis (MIM 259730). It goes
along with cerebral calciﬁcations, which can result in
mental retardation. The mutated protein is carbonic an-
hydrase type II, which is highly abundant in the osteo-
clast cytosol, synthesizing the protons transported by the
H ATPase (Sly et al. 1983). High expression of this
carbonic anhydrase in cerebral neurons and in renal in-
tercalated cells explains the associated cerebral calciﬁ-
cations and renal dysfunction, respectively.
Autosomal dominant osteopetrosis type II (ADOII,
also called “Albers-Scho¨nberg disease” [MIM 166600])
is often not diagnosed before adulthood (ﬁg. 6). The ﬁrst
signs are abnormal fractures or a suspicious appearance
of the bones in routine x-rays, especially the so-called
“sandwich vertebra” (Be´nichou et al. 2000). Cranial-
nerve compression is rare. Whereas in malignant reces-
sive osteopetrosis bone resorption seems to be entirely
abolished, bone accumulates in several steps during
growth in ADOII to remain stable during later life. Re-
cently, dominant missense mutations in the CLCN7
chloride channel gene were found, which are spread over
the whole protein, often in the direct vicinity of recessive
mutations (Cleiren et al. 2001). A mutation hotspot is
the second cystathionine b-synthase domain, which is
probably involved in protein-protein interaction.
The related sclerosing disorder, pycnodysostosis
(MIM 265800), from which the painter Toulouse-Lau-
trec is thought to have suffered, is ascribed to mutations
in cathepsin k, an acidic protease secreted by the osteo-
clast. The phenotype is milder than that of the recessive
osteopetroses, with short stature, bone fragility, skull
deformity, and hypoplasia of the clavicles being the main
symptoms (Gelb et al. 1996). Cathepsin k is indispen-
sable for bone resorption, since it is the only protease
able to cleave the intact collagen triple helix, which ren-
ders it accessible for other osteoclast proteases—for ex-
ample, MMP-9. Cathepsin k–deﬁcient osteoclasts are
therefore not able to degrade collagen but can still de-
mineralize the underlying bone, showing that acid se-
cretion is unaffected (Gowen et al.1999).
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